Association between side effects and blood microRNA expression levels and their targeted pathways in patients with major depressive disorder treated by a selective serotonin reuptake inhibitor, escitalopram: a CAN-BIND-1 report.. Int J Neuropsychopharmacol.. 2019.
Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: consensus and controversies.. Bipolar Disord. 7 Suppl 3:5-69.. 2005.
The comparative effectiveness of electroencephalographic indices in predicting response to escitalopram therapy in depression: A pilot study.. J Affect Disord. 227:542-549.. 2017.
Discovering biomarkers for antidepressant response: protocol from the Canadian biomarker integration network in depression (CAN-BIND) and clinical characteristics of the first patient cohort.. BMC Psychiatry. 16:105.. 2016.
Integrated genome-wide methylation and expression analyses reveal functional predictors of response to antidepressants.. Transl Psychiatry. 9(1):254.. 2019.
MicroRNAs 146a/b-5 and 425-3p and 24-3p are markers of antidepressant response and regulate MAPK/Wnt-system genes.. Nat Commun. 8:15497.. 2017.
Predicting Worsening Suicidal Ideation With Clinical Features and Peripheral Expression of Messenger RNA and MicroRNA During Antidepressant Treatment.. J Clin Psychiatry. 80(3). 2019.
A randomized, crossover comparison of ketamine and electroconvulsive therapy for treatment of major depressive episodes: a Canadian biomarker integration network in depression (CAN-BIND) study protocol.. BMC Psychiatry. 20(1):268.. 2020.